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Background: Angiogenesis, which is initiated by certain tumor micro-environmental conditions and diverse protein
factors, plays a pivotal role during tumor development and metastasis. Therefore, many efforts have been made to
develop effective anti-angiogenic agents as anticancer therapeutics. In the current study, we investigated the
anti-angiogenic potential of an ethanol extract of Annona atemoya seeds (EEAA) in vitro and in vivo.
Methods: The anti-angiogenic potential of EEAA was evaluated using various in vitro/in vivo models, including cell
proliferation, migration, and tube formation by human umbilical vascular endothelial cells (HUVECs); a Matrigel plug
assay; and tumor-induced angiogenesis. The expression of hypoxia-inducible factors (HIFs) and vascular endothelial
growth factor (VEGF) was investigated using reverse transcription-polymerase chain reaction, immunoassays, and
western blotting.
Results: EEAA was able to significantly inhibit the angiogenic properties of HUVECs in vitro as well as angiogenic
factor-induced blood vessel formation in vivo. EEAA down-regulated the expression of VEGF and HIF-1alpha/2alpha
at the mRNA and protein levels, respectively, in cancer cells under hypoxic conditions.
Conclusions: EEAA shows a strong anti-angiogenic potential in both in vitro and in vivo systems, and we suggest
that EEAA may be a valuable herbal source for anticancer drug development.
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Angiogenesis, the formation of new blood vessels from
pre-existing vasculature [1], is a complex cellular process
that consists of endothelial cell proliferation, migration,
and differentiation and differs from vasculogenesis,
which occurs during embryonic development [2]. Angio-
genesis is observed during embryonic vascular develop-
ment, wound healing, and organ regeneration [3]. In
adults, angiogenesis is only observed in specific areas,
such as the endometrium and ovarian follicle cells [4].
Pathologically, angiogenesis is closely related to diverse
diseases, particularly cancer. Angiogenesis promotes
tumor growth by continuously supplying nutrients and
oxygen to the tumor and removing metabolic wastes* Correspondence: nosookim@kiom.re.kr
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unless otherwise stated.produced by tumor cells [5]. In fact, the volume of a
tumor cannot exceed >1 mm3 in an avascular state [6].
Metastasis is also initiated by tumor angiogenesis.
Tumor cells release chemotactic factors such as vascu-
lar endothelial growth factor (VEGF), and these pro-
angiogenic factors recruit endothelial cells to tumors
[7,8]. Since angiogenesis was first postulated by Folk-
man in 1971 [9], it has been considered an intriguing
target for developing novel anticancer therapeutics.
Additionally, many efforts have been dedicated to devel-
oping effective inhibitors targeting angiogenesis, such as
natural endogenous inhibitors (e.g., angiostatin), endo-
thelial cell growth inhibitors (e.g., TNP-40), neutralizers
of pro-angiogenic molecules (e.g., VEGF receptor anti-
bodies), and enzyme inhibitors modulating basement
membrane structures (e.g., matrix metallopeptidase in-
hibitors) [7]. The advantage of anti-angiogenesis as an
anticancer target is that it is a common feature of tu-
mors irrespective of their type, and the development ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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due to their low mutagenesis rate [6].
Annonaceae is a family composed of more than 130
genera and 2,300 species worldwide, which are almost
exclusively tropical trees and shrubs [10]. Powdered
seeds and leaves of Annona squamosa L. have tradition-
ally been used to treat head and body lice [11]. Addition-
ally, an A. squamosa seed extract is toxic to the cabbage
looper, Trichoplusia ni [12]. A. cherimola Mill. seed ex-
tract displays a potential for insecticidal use [13]. In
1907, A. atemoya was first produced by Wester by cross-
ing A. squamosa and A. cherimola [10]. Crude extracts
of A. atemoya seeds can potentially be used in botanical
insecticides, and bullatacin, which is an annonaceous
acetogenin isolated from Annona atemoya, has been re-
ported to induce apoptotic cell death in the human
2.2.15 hepatocarcinoma cell line by reducing intracellu-
lar cAMP and cGMP levels [14,15]. Fu et al. reported
that the annonaceous acetogenin 89–2, isolated from A.
atemoya, is cytotoxic to multidrug-resistant (MDR)
KBv200 cells and to chemotherapy-sensitive parental KB
cells in vitro, and can successfully inhibit the growth of
KBv200 and KB xenografts in nude mice [16]. Fu et al.
further suggested that 89–2 shows the potential to inhibit
P-glycoprotein activity in KBv200 cells as a mechanism to
overcome MDR. However, the effect of the ethanol extract
of Annona atemoya seeds (EEAA) on angiogenesis and its
underlying mechanism remain unknown. In this study, we
demonstrated that EEAA exhibits anti-angiogenic poten-
tial both in vitro and in vivo. To our knowledge, this re-
port is the first to demonstrate the anti-angiogenic effect
of a crude extract of A. atemoya seeds.
Methods
Preparation of EEAA
A. atemoya seeds were purchased from Hannong Bio
Industry (Jeju, Republic of Korea). The identity of the A.
atemoya seeds was identified by Dr. Go Ya Choi of the
Basic Herbal Medicine Research Group, Herbal Medicine
Research Division, Korea Institute of Oriental Medicine
(KIOM), Daejeon, Republic of Korea. A voucher specimen
(KIOM010068) was deposited at the KM-Based Herbal
Drug Research Group, Herbal Medicine Research
Division, KIOM. Dried A. atemoya seeds (200 g) were
finely pulverized and immersed in 70% (v/v) ethanol
(100 g/L). Solvent extraction was performed by subjecting
the mixtures to two cycles of ultrasonication for 1 h. The
extracts were filtered through Whatman No.2 filter paper
and concentrated in a rotary evaporator. The powdered
extract (EEAA, 20.98 g) was homogenized using a mortar
and stored at 4°C until use. The yield of the final extract
was 10.49% (w/w). The EEAA was dissolved in dimethyl
sulfoxide (DMSO, Sigma, St Louis, MO, U.S.A.) at a
concentration of 2 mg/mL and stored at −70°C until use.Cell culture
Human umbilical vein endothelial cells (HUVECs) were
obtained from Lonza (Walkersville, MD, U.S.A.). The
HUVECs were maintained in EGM-2 endothelial growth
medium (Lonza) supplemented with 2% fetal bovine
serum (FBS), 0.4% fibroblast growth factor-2 (FGF2),
0.1% VEGF, 0.1% R3-insulin-like growth factor-1, 0.1%
epidermal growth factor, 0.04% hydrocortisone, 0.1% as-
corbic acid, 0.1% heparin, and 0.1% GA-100 at 37°C in a
humidified atmosphere containing 5% CO2. The culture
medium was replaced with fresh medium every other
day, and the cells were used for experiments only be-
tween passage numbers 5 and 10. A human non-small
cell lung carcinoma cell line, NCI-H460, was obtained
from the American Type Culture Collection (Manassas,
VA, U.S.A.) and was maintained in RPMI 1640 medium
supplemented with 10% FBS, 100 units/mL penicillin,
and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA,
U.S.A.).
Cell viability
One day before drug treatment, HUVECs were seeded at
a density of 5 × 104 cells/well in a 24-well tissue culture
plate containing 500 μL of EGM-2. After 24 h of drug
treatment, the culture media were saved, and the cells
were trypsinized and then resuspended in the retained
culture media. The numbers of viable and dead cells
were automatically determined using an ADAM-MC
automatic cell counter (NanoEnTek, Seoul, Republic of
Korea) as previously described [17].
Cell migration assay
Once HUVEC growth reached confluence, scratches
were introduced with a 200 μL yellow pipette tip and
photographs were taken using an inverted microscope
(Olympus IX71, Tokyo, Japan). The cells were washed
with fresh EGM-2 medium and further incubated in
fresh EGM-2 medium containing various concentrations
of EEAA. After 18 h, photographs were taken, and
wound healing was digitally quantified using the Meta-
Morph image analysis software (Molecular Devices,
Downingtown, PA, U.S.A.). The healing area (%) was
calculated according to the following formula: healing
area (%) = [1-wounded area (t = 12 h)/wounded area
(t = 0 h)] × 100.
Tube formation assay
The formation of three-dimensional tubes by HUVECs
was induced using a Cultrex in vitro angiogenesis assay
kit (Trevigen, Gaithersburg, MD, U.S.A.) according to
the manufacturer’s instructions. HUVECs resuspended
in EGM-2 media containing various concentrations of
EEAA were added in a 96‐well plate pre-coated with base-
ment membrane extracts (BMEs). After 8 h of cultivation
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The tube length and branch points were digitally quanti-
fied using the MetaMorph image analysis software.
In vivo angiogenesis assay
A directed-in vivo angiogenesis assay kit (Trevigen) was
used to investigate the effect of drugs on in vivo angio-
genesis induced by pro-angiogenic factors (VEGF and
FGF2) as previously described [17]. Briefly, angioreactors
pre-filled with growth factor-reduced BME and a com-
bination of VEGF, FGF2, and EEAA were subcutane-
ously implanted into the dorsal flanks of 6-week-old
Balb/cSlc-nu/nu female mice. After 12 days, the im-
planted angioreactors were removed, and the degree of
new vessel formation was determined via FITC-lectin-
mediated quantification of vascular endothelial cells in-
filtrating the angioreactors. Fluorescence intensities were
determined using an excitation wavelength of 485 nm
and an emission wavelength of 510 nm (SpectraMax
Gemini EM, Molecular Devices). This animal study was
approved by the Institutional Animal Care and Use
Committee of the Korea Institute of Oriental Medicine
(Protocol # 12–058).
Hypoxia-inducible factor (HIF)-luciferase reporter assay
An NIH3T3 stable cell line (NIH3T3/HIF-luc) carrying
a hypoxia-responsive element (HRE)-derived luciferase
reporter system (pHIF1-Luc) was obtained from
Panomics (Fremont, CA, U.S.A.). The NIH3T3/HIF-luc
cells were maintained in DMEM basal medium supple-
mented with 10% FBS, 100 units/mL penicillin, 100 μg/
mL streptomycin, and 100 μg/mL hygromycin B (Invi-
trogen) in 5% CO2 humidified air at 37°C. Luciferase ex-
pression was induced by exposing the cells to 150 μM of
CoCl2 or hypoxic gas (1% O2, 5% CO2, N2 balanced).
After 24 h of induction under hypoxic conditions, the
cells were washed twice with ice-cold PBS, and a whole
cell lysate (WCL) was prepared using the 1X passive
lysis buffer included with the luciferase assay system
(Promega, Madison, WI, U.S.A.). Preparation of the
WCL and quantification of intracellular luciferase activ-
ities were performed according to the manufacturer’s
guide.
Immunoassay
The quantity of VEGF released from NCI-H460 cells
into the culture medium was determined using a human
VEGF immunoassay kit (R&D Systems, Minneapolis,
MN, U.S.A.) according to the manufacturer’s instruc-
tions. Briefly, the culture medium was cleared via centri-
fugation at 4,000 g for 10 min at 4°C. The recombinant
VEGF standards and cleared medium samples were loaded
into a 96-well immunoplate pre-coated with a VEGF
monoclonal antibody. The samples were incubated for 1 hat room temperature (RT). After 3 washes, a horseradish
peroxidase (HRP)-conjugated polyclonal antibody against
VEGF was added to each well and incubated for 3 h at RT.
After 3 washes, color development was initiated by adding
a substrate solution and was monitored at 450 nm using a
microplate reader (Emax, Molecular Devices). Extracellu-
lar VEGF was quantified based on the standard curve.
Real-time polymerase chain reaction
TaqMan real-time polymerase chain reaction (RT-PCR)
was performed to determine the effect of EEAA on
intracellular VEGF mRNA levels. Total RNA was pre-
pared from NCI-H460 cells that had been cultured in
the presence or absence of EEAA using the Easy-spin™
total RNA extraction kit (iNtRON biotechnology, Seoul,
Republic of Korea). The integrity of the isolated total
RNA was confirmed via agarose gel electrophoresis.
Single-stranded cDNA was synthesized from 5 μg of total
RNA using the SuperScript™ III first strand synthesis
system (Invitrogen). The pre-validated probe and pri-
mer sets for VEGF [RefSeq, NM_001025366.2; ABI ID,
Hs00900055_m1] and β-actin [RefSeq, NM_001101.3;
ABI ID, Hs99999903_m1; VIC-labeled] were purchased
from Applied Biosystems (Foster City, CA, U.S.A.). PCR
amplification and determination of the relative expres-
sion of specific genes were performed using an Applied
Biosystems 7500 Sequence Detection System.
Western blotting
Cells were washed with ice-cold phosphate buffered-
saline. Total cell lysates were prepared using ice-cold
RIPA cell lysis buffer (Thermo Scientific, Rockford, IL,
U.S.A.) containing protease (Roche, Indianapolis, IN,
U.S.A.) and phosphatase (Sigma) inhibitor cocktails. Pro-
tein concentrations were determined using the bicincho-
ninic acid assay (Pierce, Rockford, IL, U.S.A.). Equal
amounts of proteins were subjected to SDS-PAGE and
transferred to a nitrocellulose membrane (Millipore).
The protein-blotted membrane was incubated in a
blocking solution (10% skim milk) for 1 h at RT,
followed by overnight incubation at 4°C in blocking so-
lution containing a primary antibody. After 3 washes,
the membrane was incubated for 40 min at RT with
blocking solution containing an HRP-conjugated sec-
ondary antibody. The membrane was washed, and the
immunoactive bands were visualized using an ECL (GE
Healthcare, Piscataway, NJ, U.S.A.) or SuperSignal West
Femto (Pierce) chemiluminescence substrate solution.
Digital images were acquired using the Fusion-SL4 Spec-
tra chemiluminescence system (Vilber, Eberhardzell,
Germany). The primary and secondary antibodies
employed in this study were as follows: rabbit anti-
HIF-1α (Bethyl Laboratory, Montgomery, TX, U.S.A.),
rabbit anti-HIF-2α (Abcam, Cambridge, MA, U.S.A.),
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Danvers, MA, U.S.A.), and β-actin (Bio-Rad, Hercules,
CA, U.S.A.).
Tumor-induced angiogenesis
NCI-H460 cells were seeded at 3 × 106 cells/dish in a
100 mm culture dish and then incubated for 24 h in
complete growth medium. The cells were washed with
serum-free RPMI basal medium and incubated for 2 h
with basal medium supplemented with low serum (1%
FBS) with or without 10 μg/mL EEAA. Then, the cells
were transferred to a hypoxic chamber filled with hyp-
oxic gas (1% O2) for 8 h. The culture supernatant was
harvested, and cell debris was spun down via centrifuga-
tion at 4,000 g for 10 min at 4°C. The cleared culture
medium (SN) was concentrated using a 9 kDa protein
concentrator (Pierce) at 4,000 g for 25 min at 4°C. The
EEAA in the concentrated culture medium was diluted
through 4 repeated solution exchanges with fresh basal
medium (RPMI). The final 5-fold culture medium (5X
CM) was saved and stored at −70°C until use. The over-
all process is illustrated in Figure 1. HUVECs were incu-
bated in endothelial basal medium mixed with the same
volume of 5-fold concentrated medium for cell prolifera-
tion, migration, and tube formation in vitro.
Statistics
The differences in the means of continuous variables
were determined using one-way analysis of variance and
Tukey’s HSD post-hoc test. Statistical significance was
set at p < 0.05.
Results
EEAA inhibits endothelial function-related angiogenesis
in vitro and in vivo
The effects of EEAA on the angiogenic properties medi-
ated by HUVECs were evaluated in vitro. EEAA efficiently
inhibited HUVEC proliferation in a dose-dependent man-
ner (Figure 2A) and a significant inhibitory effect of EEAA
was observed at concentrations ≥ 100 μg/mL. However,Figure 1 Preparation of culture medium for tumor-induced angiogen
as described in Methods section.during the 24 h treatment period, no decrease in cell via-
bility was observed and the cells maintained viabilities of ≥
90% within this dosage range (0–100 μg/mL) (Figure 2B).
Therefore, the anti-proliferative effect of EEAA observed
in HUVECs was not due to its cytotoxicity. EEAA drama-
tically inhibited HUVEC mobility at concentrations ≥
25 μg/mL, and only 21.4% of the original wound area was
recovered by the HUVECs at 100 μg/mL (Figure 2C). In
addition HUVECs failed to form three dimensional tube
like structure on the matrix supports in the presence of
EEAA (Figure 2D). Image analysis revealed that EEAA sig-
nificantly reduced tube length and the number of joints
connecting tubes in a dose-dependent manner (Figure 2D).
Next, we investigated the effects of EEAA on the for-
mation of new blood vessels in vivo. Vessel formation
could not be observed in the absence of the pro-
angiogenic inducers VEGF/FGF2 (negative control,
Figure 2E). Massive vessel ingrowth was observed from
the open ends of the angioreactors pre-filled with matrix
gel mixed with VEGF/FGF2 (positive control), which
was dramatically suppressed by EEAA in a dose-
dependent manner (Figure 2E, left panel). Quantification
of vessel formation by labeling endothelial cells with
FITC-lectin revealed that significant anti-angiogenic ef-
fects of EEAA were observed at concentrations ≥ 25 μg/
mL, and vessel formation decreased to 23.3% in the
100 μg/mL EEAA treatment compared with the positive
control group (Figure 2E, right panel).
EEAA down-regulates HIF signaling under hypoxia
HIF signaling is known to play a pivotal role during
tumor-induced angiogenesis and metastasis under hyp-
oxic condition [18-20]. In this study, we evaluated the ef-
fect of EEAA on HIF signaling under hypoxic conditions
using an NIH3T3 stable cell line (NIH3T3/HIF-luc) carry-
ing 4 copies of HRE (5′-GTGACTACGTGCTGCCTAG-
3′) sequences in the promoter region of the luciferase
gene. As shown in Figure 3A, exposure of cells to hypoxia
(1% O2) for 24 h increased the intracellular luciferase





Figure 2 EEAA inhibits angiogenesis in vitro and in vivo. (A and B) Cell proliferation and viability of HUVECs after 24 h of EEAA treatment.
Cells were treated with 25–100 μg/mL EEAA for 24 h. Viable and dead cells were discriminated and counted using an automated cell counter, as
described the Methods section. (C) Representative images depicting HUVEC migration after EEAA treatment with the indicated concentrations.
Wound closures were measured and recorded at 0 and 18 h after injury. (D) Representative images depicting the formation of capillary-like tube
structures on Matrigel by HUVECs after 8 h of EEAA treatment with the indicated concentrations. The effects of EEAA on the formation of
capillary-like tube structures by HUVECs such as the changes in tube length and the number of joints, were quantified as described in the
Methods section. The data are presented as the relative means ± S.D. of at least three independent experiments compared with the vehicle *P <
0.05, **P < 0.01, and ***P < 0.001 compared with the vehicle-treated groups. (D and E) (E) Effect of EEAA on angiogenic factor-derived vessel
formation in vivo. Angioreactors filled with BME premixed with combinations of the angiogenic factors VEGF/FGF2 and various concentrations of
EEAA (0–100 μg/mL) were implanted into the dorsal flanks of nude mice. After 12 days, the implanted cylinders were harvested (left panel), and
vascular endothelial cells that had migrated into the BME gels of the bioreactors were quantified using FITC-lectin detection (right panel). The
negative control represents the bioreactors without VEGF/FGF2 inducers or EEAA. Relative angiogenesis was normalized to the mean of the
negative control. *P < 0.05, and ***P < 0.001 compared with the positive control group.
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ing under hypoxia in a dose-dependent manner and more
than 85% of luciferase activity was inhibited by 100 μg/mL
of EEAA.
To investigate the underlying mechanism of EEAA-
mediated down-regulation of HIF signaling activity,
intracellular level of HIF-1α/2α was determined using
western blotting. As shown in Figure 3B, exposing NCI-
H460 cells to 1% O2 (left panel) or to 150 μM CoCl2(right panel) for 24 h up-regulated the HIF-1α/2α pro-
teins, which was markedly reversed by EEAA. HIF-1β/
ARNT, which is known to be constitutively expressed,
was not affected by hypoxic stress or by EEAA. Simul-
taneous treatment with MG132 (10 μM), a proteasomal
inhibitor, could partially relieve EEAA-mediated down-
regulation of HIF-1α (Figure 3C), suggesting that EEAA
can prevent HIF-1α accumulation under hypoxia by
accelerating its proteasomal degradation.
AB
C
Figure 3 EEAA down-regulates HIF signaling via enhanced
proteasomal degradation. (A) Effect of EEAA on HIF signaling.
NIH3T3/HIF-luc cells were pre-treated with vehicle (DMSO) or with
increasing concentrations of EEAA (1–100 μg/mL) for 2 h before
exposure to hypoxia (1% O2). After 24 h, intracellular luciferase activity
was quantified. Relative luciferase activity was determined based on
comparing with mock under normoxia (20% O2). The data are presented
as the relative means ± S.D. of at least three independent experiments
compared with vehicle. ***P<0.001 compared with the vehicle groups. (B)
Effect of EEAA on HIF protein expression under gas- or chemical-induced
hypoxia. NCI-H460 cells were pre-treated with 100 μg/mL EEAA for 2 h
before exposure to hypoxic gas (1% O2) or to 150 μM CoCl2. After 24 h
of incubation, WCL was prepared and subjected to western blot
analysis. (C) Enhanced proteasomal degradation of HIF-1α via EEAA.
NCI-H460 cells were pre-treated with a combination of vehicle (DMSO)
or 10 μM MG132 and 100 μg/mL EEAA for 2 h before exposure to
hypoxic gas (1% O2). After 24 h of incubation, intracellular HIF-1α levels
were determined through western blot analysis. β-actin was used as a
loading control.
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To examine the effects of EEAA on tumor-induced
angiogenesis, we first determined the effect of EEAA on
cell proliferation and viability in NCI-H460 tumor cells.
EEAA treatment (10 μg/mL) for 24 h inhibited cellproliferation by 16.5% compared with a mock (Figure 4A,
left panel). However, cell viability was not affected by
EEAA during this incubation time (Figure 4A, right
panel). Next, we investigated whether EEAA could
down-regulate VEGF expression in NCI-H460 cells
under hypoxia. NCI-H460 cells were pre-treated with ve-
hicle or with EEAA (10 μg/mL) for 2 h and then incu-
bated under hypoxia (1% O2) in RPMI 1640 medium
supplemented with a low serum concentration (1%).
After 8 h, VEGF released by the cells into the culture
medium was quantified via ELISA. As shown in
Figure 4B, hypoxia enhanced VEGF production in NCI-
H460 cells by more than 2-fold compared with a nor-
moxia group (M, (−) 1% O2). However, EEAA was able
to reduce VEGF expression to the basal level (EA, (+)
1% O2). Vehicle did not affect hypoxia-induced VEGF
expression (V, (+) 1% O2). The VEGF concentration in
the cell-free medium (CFM) was too low to be detected,
irrespective of hypoxia induction. To understand the
mechanism underlying the down-regulation of VEGF
expression by EEAA, we determined the alterations in
intracellular levels of VEGF mRNA. Cells were pre-
treated with the vehicle or EEAA for 2 h before expos-
ure to hypoxia (1% O2). After 24 h, total RNA was
isolated and subjected to quantitative RT-PCR. As shown
in Figure 4C, VEGF mRNA levels decreased by EEAA in a
dose-dependent manner, and the maximum EEAA treat-
ment (100 μg/mL) was able to reduce VEGF mRNA to the
basal level.
EEAA inhibits tumor-induced angiogenesis
The culture medium (CM) of NCI-H460 tumor cells
was prepared as described in Figure 1. To minimize
interference from the residual EEAA in the concentrated
CM with assay, EEAA was depleted via 4 repeated solu-
tion exchanges with fresh RPMI basal medium. The effi-
cacy of CM concentration and EEAA depletion in the
5X CM was confirmed by observing 4.6-fold increase in
VEGF concentration in the 5X CM (Figure 5A) and in-
tact cell migration in the presence of 5X CM (Figure 5B),
respectively. We used this 5X CM for further experi-
ments addressing in vitro tumor-induced angiogenesis.
The CM of NCI-H460 treated with mock (H460-CM-
M) or vehicle (H460-CM-V) enhanced HUVEC prolife-
ration (Figure 5C), cell mobility (Figure 5D), and three
dimensional tube formation (Figure 5E). However, the
EEAA-treated CM (H460-CM-EA) significantly inhibited
these angiogenic properties mediated by HUVEC. Because
EEAA was able to down-regulate the expression of VEGF
under hypoxia (Figure 4B), we investigated whether the
suppression of cell growth, migration, and tube formation
via H460-CM-EA could be reversed by VEGF supple-
mentation. As expected, H460-CM-EA supplemented with
3 ng/mL VEGF (H460-CM-EV) was able to relieve the
AB C
Figure 4 EEAA decreases VEGF expression in tumor cells under hypoxic conditions. (A) Effect of EEAA on tumor cell growth. HCI-H460 cells
were treated with EEAA (10 μg/mL), and cell proliferation (left panel) and viability were determined after 48 h. (B) Reduced production of VEGF
due to EEAA. NCI-H460 cells were cultured under normoxic (20% O2) or hypoxic (1% O2) conditions in the absence (M) and the presence of
vehicle (DMSO, V) or 10 μg/mL EEAA (EA). After 8 h of incubation, an immunoassay was performed to quantify VEGF secreted from NCI-H460 cells.
(C) Down-regulation of VEGF at the transcriptional level by EEAA. NCI-H460 cells were cultured under normoxic (20% O2) or hypoxic (1% O2)
conditions in the presence of increasing concentrations of EEAA (1–100 μg/mL). After 24 h, intracellular VEGF mRNA levels were quantified using
RT-PCR. The relative mRNA contents were determined based on comparison with vehicle (DMSO). The data are presented as the mean or relative
mean ± S.D. of at least three independent experiments. *P < 0.05 and ***P < 0.001 compared with the vehicle groups.
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genic properties. These results indicate that EEAA pre-
vented angiogenesis primarily by down-regulating VEGF
production in NCI-H460 tumor cells.
Discussion
Although massive and evident non-metastatic tumors can
be eradicated through surgical intervention, the treatment
of small primary tumors or cancers undergoing metastasis
largely relies on non-invasive cancer therapies, such as ir-
radiation and chemotherapy [6]. Because angiogenesis is
an essential step during the development and metastasis
of solid tumors, strategies targeting tumor angiogenesis
for development of anticancer drugs have garnered much
attention. Angiogenesis is a nearly universal characteristic
of cancer, suggesting that anti-angiogenic drugs may
present a wide range of clinical applications for cancer
therapy [21]. Two pathways modulate angiogenesis,
endothelium-related and tumor-induced angiogenesis
pathways. Endothelium-related angiogenesis largely
depends on modulating the ability of vascular endothe-
lia cells to proliferate, migrate, and respond to pro-
angiogenic proteins, such as VEGF, basic FGF (bFGF),
interleukin 8, and transforming growth factor-β [6,22].
Tumor-induced angiogenesis is based on the ability of
tumors to modulate the expression and activity of pro-
angiogenic proteins, such as VEGF and bFGF [6,22], and
is initiated by the release of these proteins from tumor
cells, macrophages, and the extracellular matrix [23]. Pro-angiogenic factors recruit endothelial cells and promote
their proliferation in preparation for blood vessel forma-
tion. In the present study, we showed that EEAA exhibits
anti-angiogenic potential by regulating both endothelium-
related (Figure 2) and tumor-induced angiogenic pathways
(Figures 4 and 5).
Although we did not thoroughly investigate the mech-
anism, we suggested that EEAA can down-regulate VEGF
expression under hypoxia by enhancing proteasomal
degradation of its labile transcription factor, HIF-1/2α
proteins. It is known that HIFα subunits hydroxylated
by HIF-specific proly hydroxylases in the presence of O2
are subjected to degradation via the ubiquitin-proteasomal
pathway [18,24]. Previous studies demonstrating the
mechanism of action of molecules inhibiting HIF-1α ac-
tivities may provide some insight on this topic. Loss of
the tumor suppressor protein, phosphatase and tensin
homolog (PTEN) [25], and activation of the phos-
phatidylinositol 3-kinase (PI3K) pathway are related to
increased levels of the HIF-1α protein [26]. PX-12 (1-
methylpropyl 2-imidazolyl disulfide) decreases HIF-1α,
independent of the von Hippel-Lindau (VHL) protein
pathway, through irreversible inhibition of thioredoxin-1,
which inhibits PTEN, leading to activation of the PI3K/
Akt/mammalian target of rapamycin (mTOR) pathway
[27,28]. Rapamycin, which is an mTOR inhibitor, induces
apoptotic cell death in human NSCLC cell lines through
enhanced HIF-1α degradation and decreased HIF-1α −




Figure 5 EEAA suppresses tumor-induced angiogenesis by HUVECs in vitro. (A) Concentration of tumor cell-culture medium. For NCI-H460
tumor cell-induced angiogenesis, the culture medium (CM) was concentrated 5-fold using a 9 kDa protein concentrator, as described in the
Methods section and as depicted in Figure 1. The levels of VEGF in the cell-free medium (CFM), CM, and 5-fold CM (5X CM) were measured via
ELISA. (B) Efficient removal of EEAA from the concentrated CM. HUVEC migration was observed in the presence of the CM or 5X CM. (C to E) The
effect of EEAA on NCI-H460 tumor cell-induced angiogenesis mediated by HUVECs. The 5X CFM and 5X CM were prepared from cell-free (CFM) and
NCI-H460 cells (H460-CM)-culture medium (CFM), respectively, in the absence (M) or the presence of vehicle (V), EEAA (EA), and VEGF supplementation
(EV). Cell proliferation (C), migration (D), and tube formation (E) by HUVECs were determined after treatment with each concentrated culture medium.
The data are presented as the relative mean ± S.D. of at least three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the
vehicle groups.
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http://www.biomedcentral.com/1472-6882/14/353[29]. YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylinda-
zole) down-regulates HIF-1/2α at both the transcriptional
(protein synthesis) and post-transcriptional (protein stabil-
ity) levels, which are linked to the metal ion-related path-
way of O2 sensing and the murine double minute 2
protein [30-32]. As antagonists of heat shock protein 90
(hsp90), geldanamycin and 17-AAG (17-allylamino-17-
desmethoxygeldanamycin) disrupt the physical interaction
between hsp90 and HIF-1α and then promote proteaso-
mal HIF-1α protein degradation, irrespective of VHL pro-
tein or O2 tension. A naturally occurring insecticide,
deguelin, inhibits HIF-1α signaling by inhibiting de novoprotein synthesis and promoting the proteasomal protein
degradation of HIF-1α [33].
VEGF is a unique endothelial cell-specific mitogen that
promotes many events required for angiogenesis, and is
one of the important target genes regulated by HIF-1α
[34]. HIF-1α, which is a component of a transcriptional
complex that induces more than 60 genes required for tu-
mors to adapt to hypoxic stress [31], is extremely labile
under normoxia [35]. Under hypoxic conditions, HIF-1α
accumulates and translocates to the nucleus, where this
subunit interacts with HIF-1β, p300, and other transcrip-
tion factors and then binds to HRE sequences residing in
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http://www.biomedcentral.com/1472-6882/14/353promoter regions of target proteins [36]. Because HIF-1α
regulates a variety of processes, such as angiogenesis and
glucose metabolism, this subunit is broadly accepted as a
critically important tumor cell survival factor that is re-
quired for tumorigenesis and metastasis in early and late
stages of tumors, respectively [37].
Some previous reports have demonstrated the anti-
tumor effects of A. atemoya [14-16] and its parental
plants, A. squamosa [38,39] and A. cherimola [40]. How-
ever, to our knowledge, no previous study has verified
the anti-angiogenic effect of an A. atemoya extract. Wu
et al. reported that isodesacetyluvaricin, which is an
annonaceous acetogenin, isolated from A. glabra inhib-
ited the gene expression of cyclooxygenase-2 (COX-2),
whose activity is associated with inflammation and with
angiogenesis, in A431 human epidermoid carcinoma
cells [41]. In the present study, we did not investigate
the expression profile of COX-2 after EEAA treatment
in A549 human lung cancer cells. However, the relation-
ship between COX-2 and HIF-1α can be inferred from a
previous study demonstrating that COX-2 can be tran-
scriptionally up-regulated by HIF-1α under hypoxic con-
ditions and that elevated COX-2 activity promotes the
survival of colorectal tumor cells [42].Conclusions
Taken together, our findings demonstrated that EEAA ex-
hibits anti-angiogenic potentials via direct inhibition of
endothelial cell as well as tumor-mediated angiogenesis,
including down-regulation of VEGF and HIF signaling in
tumor cells. Therefore, EEAA should be considered a valu-
able herbal source for developing anticancer agents. The
limitations of the present study include the followings: 1)
we did not fully investigate the anti-angiogenic mecha-
nisms of EEAA, such as down-regulation of HIF-1α under
hypoxic conditions, and 2) we did not characterize the
molecule(s) responsible for the observed EEAA-mediated
anti-angiogenic potential.Abbreviations
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